Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 1
2009 9
2010 12
2011 13
2012 10
2013 22
2014 12
2015 12
2016 15
2017 10
2018 11
2019 13
2020 17
2021 13
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

150 results
Results by year
Filters applied: . Clear all
Page 1
Predictors of progression in systemic sclerosis patients with interstitial lung disease.
Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM. Distler O, et al. Among authors: assassi s. Eur Respir J. 2020 May 14;55(5):1902026. doi: 10.1183/13993003.02026-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32079645 Free PMC article. Review.
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Highland KB, et al. Among authors: assassi s. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1. Lancet Respir Med. 2021. PMID: 33412120 Free article. Clinical Trial.
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators. Tashkin DP, et al. Among authors: assassi s. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.
Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis.
Pachera E, Assassi S, Salazar GA, Stellato M, Renoux F, Wunderlin A, Blyszczuk P, Lafyatis R, Kurreeman F, de Vries-Bouwstra J, Messemaker T, Feghali-Bostwick CA, Rogler G, van Haaften WT, Dijkstra G, Oakley F, Calcagni M, Schniering J, Maurer B, Distler JH, Kania G, Frank-Bertoncelj M, Distler O. Pachera E, et al. Among authors: assassi s. J Clin Invest. 2020 Sep 1;130(9):4888-4905. doi: 10.1172/JCI135439. J Clin Invest. 2020. PMID: 32603313 Free PMC article.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O; SENSCIS trial investigators. Seibold JR, et al. Among authors: assassi s. Ann Rheum Dis. 2020 Nov;79(11):1478-1484. doi: 10.1136/annrheumdis-2020-217331. Epub 2020 Aug 5. Ann Rheum Dis. 2020. PMID: 32759258 Free PMC article. Clinical Trial.
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.
López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B; European Scleroderma Group†, Proudman S, Stevens W, Nikpour M; Australian Scleroderma Interest Group (ASIG), Vyse T, Herrick AL, Worthington J, Denton CP, Allanore Y, Brown MA, Radstake TRDJ, Fonseca C, Chang HY, Mayes MD, Martin J. López-Isac E, et al. Among authors: assassi s. Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y. Nat Commun. 2019. PMID: 31672989 Free PMC article.
Biomarkers in systemic sclerosis.
Skaug B, Assassi S. Skaug B, et al. Among authors: assassi s. Curr Opin Rheumatol. 2019 Nov;31(6):595-602. doi: 10.1097/BOR.0000000000000656. Curr Opin Rheumatol. 2019. PMID: 31436584 Free PMC article. Review.
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.
Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, Hant FN, Gordon JK, Shah AA, Zhu L, Zheng WJ, Browning JL, Barron AMS, Wu M, Visvanathan S, Baum P, Franks JM, Whitfield ML, Shanmugam VK, Domsic RT, Castelino FV, Bernstein EJ, Wareing N, Lyons MA, Ying J, Charles J, Mayes MD, Assassi S. Skaug B, et al. Among authors: assassi s. Ann Rheum Dis. 2020 Mar;79(3):379-386. doi: 10.1136/annrheumdis-2019-215894. Epub 2019 Nov 25. Ann Rheum Dis. 2020. PMID: 31767698 Free PMC article.
Type I interferon dysregulation in Systemic Sclerosis.
Skaug B, Assassi S. Skaug B, et al. Among authors: assassi s. Cytokine. 2020 Aug;132:154635. doi: 10.1016/j.cyto.2018.12.018. Epub 2019 Jan 23. Cytokine. 2020. PMID: 30685202 Review.
150 results